Терапевтические возможности холинолитиков у больных хронической обструктивной болезнью легких

1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. N H L B I/ W H O workshop report.— National Heart, Lung, and Blood Institute. Publication 2701,2001.

2. Vereire P. The burden of chronic respiratory pulmonary disease. Respir. Med. 2002; 96 (suppl.C): S3-S10.

3. Barnes P. The pharmacological properties of thiotropium. Chest 2000; 117 (2, suppl.): 63S-66S.

4. Barnes P. Theoretical aspects of anticholinergic treatment. In: Gross N., ed. Anticholinergic therapy in obstructive airways dis ease. London: Franklin Scientific Publications; 1993. 88-104.

5. Barnes P., Belvesi M.G. et al. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist the treatment of obstructive airways disease. Life Sci. 1995; 56 (11-12): 853-859.

6. Donahue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122 (1): 47-55.

7. Martin R.J., Barielseon B.L., Smith P. et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999; 115 (5): 1338-1345.

8. Leisker J.J., Van De Velde V et al. Effect of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir. Med. 2002; 96 (8): 559-566.

9. Levin D.C., Little K.S., Laughlin K.R. et al. Addiction of anticholinergic solution prolongs bronchodilating effect of (32-agonists in patients with chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (1A): 40S-48S.

10. Taylor ]., Kotch A., Rice K. et al. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest 2001; 120 (4): 1253-1261.

11. Leisker J.J., Wijkstra P.J., Hacken T. et al. A systematic review of the effect of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121 (2): 597-608.

12. Matera M.G., Cazzola M., Vinciquerra A. et al. A comparison of the bronchodilating effects of salmeterol, saibutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. 1995; 8 (6): 267-271.

13. Chrischilles E., Gilden D., Kubisiak J. et al. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease:effectiveness of two-in-one inhaler versus separate inhalers. Am. J. Manag. Care 2002; 8 (10): 902-911.

14. Friedman M., Serby C.VZ., Menjoge S. et al. Pharmacoecono mic evaluation of a combination of ipratropium plus albuterol compared with iptaropium and albuterol alone in COPD. Chest 1999; 115 (3): 635-641.

15. Chapman K.R., Arvidsson P., Chuchalin A.G. et al. The additional of salmeterol 50 meg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. Can. Respir. J. 2002; 9(3) : 178-185.

16. Dlsse B., Speck G.A., Rominger K.L. et at. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64 (6-7): 457-464.

17. Gupta R.K. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease. Indian J. Chest Dis Allied Sci. 2002; 44 (3): 165-172.

18. Jarvis B., Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drug Aging 2001 * 18 (6): 441-472.

19. Sichletldis L., Kottakis J., Marcou S. et al. Bronchodilatory response to formoterol, ipratropium, and their combination in patients with stable COPD. Int. J. Clin. Pract. 1999; 53 (3): 185-189.

20. Adkison J.D., Konzem S.L. Management of acute exacerbations of chronic obstructive pulmonary disease. Pharmacotherapy 2001; 21 (8): 929-939.

21. Hunter M.H., King D.E. COPD: management of acute exacerbations and chronic stable disease. Am. Fam. Physician. 2001; 64(4) : 603-612.

22. McCrory D., Brown C., Gelfand S.E., Baqch P.B. Management of acute exacerbations of COPD. A summary and appraisal of published evidence. Chest 2001; 119 (4): 1190-1200.

23. McCrory D., Brown C D. Inhaled short-acting P2_a&on*sts versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2001; 2- CD 002984.

24. McCrory D., Brown C D. Anti-cholinergic bronchodilators versus P2-sympatomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev 2002. 4: CD 003900.

25. Snow V., Lascher S., Mottur-Pilson C. et al. The evidence base for management of acute exacerbations of COPD. Clinical practice guideline. Chest 2001; 119 (4): 1185-1189.

26. Casaburi R., Mahler D.A., Johnes P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19 (2): 217-224.

27. van Noord J.A., Bantie Th. A, Eland M.E. et al. A randomized controlled comparison of titropium and ipratropium in the treatment of COPD. Thorax 2000; 55 (4): 289-294.

28. Vincken W., van Noord A.P.M., Greefrost Th. A. et al. Improvement health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19 (2): 209-216.

29. D'Urzo A.D., De Salvo M.C., Ramirea-Rivera A. et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3 week, randomized, double blind, within- patient, multicenter study. Chest 2001; 119 (5): 1347-1356.

30. van Noord J.A., Smeets J.J., Custers F.L.J. et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19 (4): 639-644.

31. O'Donnel D.E., Lam M., Webb K.A. Spirometric correlated of improvement in exercise performance after cholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542-549.

32. Sin D.D., Tu J.V. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax 2000; 55 (3): 194-197.

33. Ayers M.L., Mejia R., Ward J. et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur. Respir. J. 2001; 17 (6): 1132-1137.